Amydis

The core of Amydis's business is the development of proprietary, patent-protected small molecule fluorescent tracers. These tracers are designed to be administered to a patient and then bind to specific misfolded protein deposits, or biomarkers, in the retina and other ocular tissues. These biomarkers, such as amyloid-beta, alpha-synuclein, and TDP-43, are hallmarks of various debilitating conditions including Alzheimer's disease, Parkinson's disease, glaucoma, and Amyotrophic Lateral Sclerosis (ALS). Once bound, the tracers generate a signal that can be detected and quantified using standard imaging cameras commonly found in eye care practices.

This approach offers a significant advantage over current diagnostic methods, which are often invasive, expensive, or only effective at later stages of disease. By enabling detection at the molecular level, potentially before clinical symptoms arise, Amydis aims to accelerate diagnosis, facilitate the development of new therapies, and allow for earlier, more effective patient intervention. The company is targeting a broad market, from neurologists and specialists to primary eye care providers, who could integrate this screening into routine exams. The business model appears to be centered on obtaining regulatory approval for its diagnostic platform, which would then be utilized by healthcare professionals and pharmaceutical companies conducting clinical trials. The company has successfully raised capital through venture funding and has been awarded significant grants from the National Institutes of Health (NIH) and The Michael J. Fox Foundation to advance its clinical programs.

Amydis is actively conducting human clinical trials for its tracers. For instance, its candidate AMDX-2011P is in Phase 2 trials for detecting amyloid-beta in glaucoma patients and has received FDA guidance for development as a diagnostic for cerebral amyloid angiopathy (CAA). The company is also creating a multi-omics data warehouse, combining its unique ocular biomarker data with genomics and blood biomarkers to power AI-driven insights for precision medicine. This positions Amydis not just as a diagnostics developer, but as a data-driven health insights company aiming to transform patient outcomes in ophthalmology, neurology, and cardiology.